Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity - Wikidata - awgldk - TriplyDB

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

http://www.wikidata.org/entity/Q27650811

about

T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Genetic correlates influencing immunopathogenesis of HIV infection Immediate-type hypersensitivity drug reactions Drug allergy: causes and desensitization Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses Abacavir-reactive memory T cells are present in drug naïve individuals Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.Genotyping for severe drug hypersensitivity.PharmGKB summary: abacavir pathway Antiviral drug allergy.Pharmacogenetics of drug hypersensitivity.Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers T cell receptor recognition of self and foreign antigens in the induction of autoimmunity.The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope T cell-mediated hypersensitivity reactions to drugs Delayed drug hypersensitivity: models of T-cell stimulation Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1.A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions.Adversomics: a new paradigm for vaccine safety and design.Individualization of antiretroviral therapy.Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.Testing for drug hypersensitivity syndromes.Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

P2860

Q26747638-CB059700-1A29-43D3-81AC-46ABF46F7808 Q26779078-EB8DF8A0-0520-41E4-85F9-7F51FA5AB247 Q26800973-B45AE972-93F7-4B67-BE45-7F368B64B46B Q26800980-DA9C8A8A-4041-475C-9F57-B22D25D75E75 Q26827459-95191F46-ACD7-47AA-A57B-80E2BB9E5127 Q26995860-AA9DC0D1-268E-4762-AAF7-ECC67569570E Q27012238-E35A7B12-A653-4410-893F-C781B044E7B3 Q27335598-6996A470-9758-4692-A4EE-1F04EEFB1913 Q27675160-C5EDC15F-0446-4CB5-BFD1-5CF6DB18C1EF Q27675174-CFE0EBDD-576E-4122-9894-D65C6AE923B1 Q27678022-65F9C734-DFF2-48C6-86D8-1E57EDF7228F Q27679355-38486941-5236-4A9E-A708-358F26A9B9A7 Q27690772-89B287C9-EEE5-4C3B-9D0F-0E2C864886FE Q27692095-55070F67-3D1D-4E26-9369-6125C83A9738 Q28080256-182F4778-CBF7-4E4D-88DC-419DC29788B1 Q28477582-CC70CAB4-9330-4AE5-BB4D-216C6F94B840 Q28538078-6E4F13FD-7FC1-44A5-BFAB-AAE7DE40776E Q28543405-0297EE97-6DA9-4989-83D1-8C267D3415E5 Q28547607-D1207A06-5EFA-4770-877D-03B570B9FAF9 Q29417159-4A5992A6-14BF-4928-8675-CCEF4F3923FC Q33582530-46CB7EE9-70F9-4EBA-B41A-ADD69E7BB2CB Q33819062-43199CBA-B325-425D-B99D-E13453C49F96 Q34075812-6D1E5C96-928E-42CD-9C10-E69469376E89 Q34118186-86CB2F8A-5526-4696-8B70-4CB80C26CE3D Q34140322-8DEFB5AD-4174-467A-B747-B79C5459C2EF Q34316771-E96D071D-8250-4E6B-9882-6EF996415E43 Q34777861-0C7BD671-58C3-4726-8F77-F4B644AEB52B Q34810328-CD4F26F4-347F-4A13-878E-7F8A946DD205 Q34971993-6543EC92-9A84-46B3-A304-E396FCBC65E6 Q34976476-C7BC8B44-36FB-49D7-8E81-D60BEE3F18A2 Q34994754-9CF7BCA4-960A-441F-AF71-FF923218141F Q35641485-BFB5399D-5F8A-40DE-B82C-E5829D23CF0A Q35985659-04FF53BD-75F4-45EB-9FCB-C6290BFD14A3 Q36089652-23CE734C-ADAC-43B5-AFED-C5D0C33BAD7D Q36242667-3AB85524-5BFA-4CBF-AD73-8C54FE94A14F Q36441423-3BD0E62A-B4E4-4C5A-B477-6278E6832A99 Q36762374-3F6B19CA-6900-48FD-8E82-49E28BAF4458 Q36766056-B7DAD82C-50E9-4E8E-BEDC-C08FB6E0D07F Q36863181-7B8254CE-FE2D-42C2-9AE2-865B43E08AAE Q37121662-EB162910-330E-4A7F-B2A5-82D06F6B2CEB

P2860

Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity

http://www.wikidata.org/entity/Q27650811

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Human leukocyte antigen class ...... systemic drug hypersensitivity

@ast

Human leukocyte antigen class ...... systemic drug hypersensitivity

@en

Human leukocyte antigen class ...... systemic drug hypersensitivity

@nl

type

label

Human leukocyte antigen class ...... systemic drug hypersensitivity

@ast

Human leukocyte antigen class ...... systemic drug hypersensitivity

@en

Human leukocyte antigen class ...... systemic drug hypersensitivity

@nl

prefLabel

Human leukocyte antigen class ...... systemic drug hypersensitivity

@ast

Human leukocyte antigen class ...... systemic drug hypersensitivity

@en

Human leukocyte antigen class ...... systemic drug hypersensitivity

@nl

P1433

Q27650811-06677177-4B72-4A1D-8D37-BC66E89D7F75

P1476

Q27650811-FD0B8B7A-BE95-4DB6-B749-5DD3E31833FE

P2093

Q27650811-12FDE1CD-D2C6-4C95-AC26-9D17B13C2C1F

Q27650811-243B4C5B-B506-4905-ABA1-99A7652CE06B

Q27650811-2C6C093C-D462-4AE7-9CDA-EDD756C5FEE9

Q27650811-2DC42AC9-5C2D-4DD7-A591-4C1CD49A888A

Q27650811-6B10F82E-60D1-48B3-81C9-AB422D581183

Q27650811-6E5C1F70-2C10-4524-B699-8D3550186102

Q27650811-84C8033B-27B9-4A61-B5CC-4554360FEFE4

Q27650811-AADC51C9-0975-4981-A276-E096B322AEF6

Q27650811-B1D258F2-75C3-47D8-A1E1-48DA01A9781B

Q27650811-D152960E-E220-4E6E-834F-05F969C6A128

P304

Q27650811-F5B3ACF1-69F3-4CAF-8E3F-865E49617841

P31

Q27650811-3FADC9D3-41CD-490F-B4A2-D19AC81F4EC6

P3181

Q27650811-73488560-6E61-40E6-BD7B-B1A0F380AEFE

P356

Q27650811-EC17E450-05A2-4285-BC1C-77EBC890B816

P407

Q27650811-18D1B515-2375-43EF-AC95-6968F0095A46

P433

Q27650811-6C956A52-0207-40A6-8941-A8BBF77D3410

P478

Q27650811-7908D3CD-AB83-41D7-95FE-4BA92100AD77

P50

Q27650811-2B399D31-D637-48E6-9A18-F8DE934607BE

Q27650811-36771CE5-42A1-452E-B4E4-F571BC23F0F7

Q27650811-9520EC1C-6CBE-4FCE-A322-19E9C6BA91B6

Q27650811-A07D7202-F892-42AE-A75F-D734455854F2

Q27650811-A45DAF8E-B407-4DF1-B094-7DC3BA8D9DF7

Q27650811-BC3BCB67-26ED-4460-AFA2-711A51FA0CEA

Q27650811-EE8F2C65-E365-40C9-BF68-3A4C9537AA42

P577

Q27650811-F59A7864-9CD6-462B-BAF4-C349A0CDADFC

P5875

Q27650811-3454E33B-4394-4632-A1BE-3892F8C3238B

P698

Q27650811-23C48661-8525-402D-B9AB-21ABC7E5D442

P921

Q27650811-0B2271B8-795C-466D-861E-2D0240C92D4F

Q27650811-9EB936CE-0A1B-4D24-B990-4E86A9DDBB8B

Q27650811-B7496EF1-F102-4038-B83E-73330FB160CC

Q27650811-FE869A87-7925-4305-B7EA-FC031D5DEACF

P3181

P356

J.IMMUNI.2008.04.020

P1433

P1476

Human leukocyte antigen class ...... systemic drug hypersensitivity

@en

P2093

Anthony D Kellerher

http://www.w3.org/2001/XMLSchema#string

Brian D Tait

http://www.w3.org/2001/XMLSchema#string

Coral Ann Almeida

http://www.w3.org/2001/XMLSchema#string

David Nolan

http://www.w3.org/2001/XMLSchema#string

Debbie Marriott

http://www.w3.org/2001/XMLSchema#string

Diana Chessman

http://www.w3.org/2001/XMLSchema#string

Mandvi Bharadwaj

http://www.w3.org/2001/XMLSchema#string

Nicole A Mifsud

http://www.w3.org/2001/XMLSchema#string

Rhonda Holdsworth

http://www.w3.org/2001/XMLSchema#string

Simon Mallal

http://www.w3.org/2001/XMLSchema#string

P304

822-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2010993

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.IMMUNI.2008.04.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Lars Kjer-Nielsen

James McCluskey

Anthony W. Purcell

Nicholas A. Williamson

Lyudmila Kostenko

Julia K Archbold

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5306876

http://www.w3.org/2001/XMLSchema#string

P698

18549801

http://www.w3.org/2001/XMLSchema#string

P921